Santiago LD, Rivas AS

Idioma: Español
Referencias bibliográficas: 23
Paginas: 104-107
Archivo PDF: 103.83 Kb.

FRAGMENTO

La enfermedad de Parkinson (PD) está caracterizada por una degeneración progresiva de las neuronas dopaminérgicas y una reducción en la concentración de la dopamina (DA). Así mismo en estudios post mortem se ha reportado presencia de inclusiones citoplásmicas compuestas principalmente de α-sinnucleína. El estrés oxidativo, la disfunción mitocondrial y la respuesta inflamatoria, contribuyen a la progresión de la enfermedad. Por otro lado, se han reportado estudios donde la DA y sus metabolitos oxidados están involucrados en el daño a neuronas dopaminérgicas.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Tanner CM, Goldman SM. Epidemiology of Parkinson´s disease. Neurol Clin 1996; 14: 317-335.

2. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 197-211.

3. Braak H, Ghebremedhim E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson´s disease-related pathology. Cell Tissue Res 2004; 318: 121-134.

4. Giroux ML. Parkinson disease: Managing a complex, progressive disease at all stages. Cleav Clin J Med 2007; 74: 313-328.

5. Méndez-Álvarez E, Soto-Otero R. Dopamine: A double-edged sword for the human brain. Recent Res Devel Life Sci 2004: 2, 219-220.

6. Roland GW, Staal, Sonsalla PK. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-Methy-4phenylpyridinium neurotoxicity in vivo in rat striatal. J Pharmacol Exp Ther 2000; 74: 313-328.

7. Olanow CA. A radical hypothesis for neurodegeneration. TINS 1993: 6, 439-444.

8. Ramsden DB, Parsons RB, Ho SL, Waring RH. The etiology of idiopathic Parkinson’s disease. Mol Pathol 2001; 54(6): 369-380.

9. Enochs WS, Sarna T, Zecca L, Riley PA, Swartz HM. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson’s disease: a hypothesis. J Neural Transm Park Dis Dement Sect 1994; 7(2): 83-100.

10. Zecca L, Zucca FA, Albertini A, Rizzio E, Fariello RG. A proposed dual role of neuromelanin in the pathogenesis of Parkinson’s disease. Neurology 2006; 67(7 Suppl. 2): S8-11.

11. Bisaglia M, Mammi S, Bubacco L. Kinetic and structural analysis of the early oxidation products of dopamine: Analysis of the interactions with {alpha}-synuclein. J Biol Chem 2007; 282(21): 15597-605.

12. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006; 97(6): 1634-1658.

13. Ischiropoulos H, Beckman JS. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest 2003; 111 (2): 163-169.

14. Jenner P. Oxidative stress in Parkinson’s disease Ann Neurol 2003; 53: S26-36; discussion S36-8.

15. Barja C, Herrero A. Oxidative damage to mitochondrial DNA is inversely related to maximum life span in the heart and brain of mammals. FASEB 2000: 14, 312-318.

16. Cohen G. Monoamine oxidase, hydrogen peroxide, and Parkinson´s disease. Adv Neurol 1987: 45, 119-125.

17. Graham DG. Oxidative phatways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978: 14, 133-643.

18. KanKaanpââ Aino, Esa Meririnne, Kari Ariniemi, Timo Sépala. Oxalic acid stabilizes dopamine, serotonin, and their metabolites in automated liquid chromatography with electrochemical detection. J Chromatography B 2001; 53: 413-419.

19. Schapira AH, Cooper JM, Dexter D. Mitochondrial complex I deficiency in Parkinson´s disease. J Neurochem 1990; 54: 823-827.

20. Beal F. Excitotoxicity and nitric oxide in Parkinson´s disease pathogenesis. Ann Neurol 1998; 44: 110-114.

21. Olanow CW, McNaught KS. Ubiquitin-proteasome system and Parkinson’s disease. Mov Disord 2006; 21(11): 1806-1823.

22. Lotharius J, Brundin P. Pathogenesis of Parkinson’s disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosc 2002; 3: 932-942.

23. LaVoie MJ, Ostaszeweski BL, Weihofen A, Schlossmacher MG, Selkoe DJ, Dopamine covalently modifies and functionally inactivates parkin. Nat Med 2005; 11: 1214-1221.